Osimertinib Re-challenge for EGFR-mutant NSCLC after Osimertinib-induced Interstitial Lung Disease: A Case Report
Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in some patients. We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with o...
Saved in:
Main Authors: | , , , |
---|---|
Format: | article |
Language: | ZH |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/08ac61b7c38540368ddbabbcc8b08745 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|